explore -WSS

explore

author：explore 2025-08-11 09:47:43 - browse：3

A psilocybin mushroom lays inside a clear capsule — Adobe

A single dose of psilocybin may have enduring benefits for people with major depressive disorder, according to a randomized clinical trial published Thursday in the Journal of the American Medical Association.

Several prior studies have suggested that psilocybin, the psychedelic compound produced by certain types of mushrooms, could be a promising way to treat major depression in people for whom antidepressants or counseling aren’t effective. But those studies mostly focused on short-term results, while the new JAMA study looked at psilocybin’s efficacy up to six weeks after the administration of a single dose of psilocybin.

“It’s exciting to see another study that’s coming out that is adding to the evidence base suggesting potential efficacy of psilocybin for depression, amongst other conditions,” said Greg Fonzo, an assistant professor and co-director for the Center for Psychedelic Research and Therapy at the University of Texas at Austin’s Dell Medical School, who was not involved in the study.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Healthy food access boosts outcomes in two studies

knowledge

WSS

First transplant of an entire human eye performed

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Readout Newsletter: Allogene's pivot, Illumina exec to lead Delfi

Ohio still needs to do more to protect the right to abortion

Burning questions for the 2024 JPM Healthcare Conference

Ventyx halts psoriasis drug development after lackluster trial results

hotspot

explore

focus

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

What health policies could hitch a ride on a spending bill?

Activists slam private health insurers over coverage restrictions

A letter from the executive editor: STAT UnitedHealth investigation

Peter Hotez and the public health issue of online harassment

Feng Zhang CRISPR delivery startup lays off quarter of staff

United colonoscopy coverage change 'may cost lives,' doctors say

Goldman Sachs launches $650M fund for life science investments

Medicare details structure of new drug price negotiation program

Healthy food access boosts outcomes in two studies

hotspot

Eli Lilly’s chief scientist on obesity drugs, gene editing, and more

Antibiotic resistance and the global rise in human conflict

Readout LOUD Podcast: Lilly's obesity drug, the power of radiation

Healthy food access boosts outcomes in two studies

Chronically ill young patients struggle to find fertility info

Feng Zhang, Grail founder join forces on new gene editing startup

hotspot

focus

knowledge

focus